Priovant Therapeutics
NC - DurhamBiotechnology
Focus: Priovant Therapeutics is a Durham, NC-based biotechnology company focused on autoimmune therapies, particularly in immunology. The company is actively recruiting across 55 open positions and advancing multiple clinical-stage programs.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Open Jobs
43-5 this month
Cooling — net -5 jobs in 30d
0 added, 5 removed. Slower than typical.
Should You Work at Priovant Therapeutics?
AI assessmentBest suited for early-to-mid career professionals seeking clinical-stage exposure with autoimmune focus; financial transparency and scientific publication record should be clarified during due diligence.
Why Work Here
- Active Phase 3 pipeline in high-unmet-need indications (uveitis, dermatomyositis) suggests near-term catalysts and commercial opportunity
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Oral Brepocitinib
Cutaneous SarcoidosisClinical Trials (2)
NCT07532603A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
Phase 2/3Help build intelligence for Priovant Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.